Medicine guide

Cotronak

·

  • Prescription status not stated
  • Antibiotics, antivirals and antifungals taken into the body
Active substance
Ribavirin
Made by
Schering-Plough Europe

Quoted from the official source. Not yet reviewed by Mediclarum — the leaflet in your pack is authoritative.

What it is for

  • Cotronak is indicated for the treatment of chronic hepatitis C and must only be used as part of a combination regimen with peginterferon alfa-2b or interferon alfa-2b. Cotronak monotherapy must not be used.There is no safety or efficacy information on the use of Cotronak with other forms of interferon (i.e., not alfa-2b).Please refer also to the peginterferon alfa-2b or interferon alfa-2b Summary of Product Characteristics (SPC) for prescribing information particular to that product.

From the official label · 2026-09-30 · European Medicines Agency

Same active substance, strength and form in other countries

Matched on active substance, strength and kind of form only. This is not a statement that the products are equivalent or interchangeable: other ingredients, release and approved uses can differ — ask a pharmacist before swapping.

Medicine passport: one printable page to show a pharmacist abroad

United StatesNo exact match for this strength and form

CanadaNo exact match for this strength and form

Details

Made bySchering-Plough Europe
Active substanceRibavirin
Used inAntibiotics, antivirals and antifungals taken into the body
ClassificationJ05AB04 · Antibiotics, antivirals and antifungals taken into the body
Authorised on1999-05-07
Last updated by the regulator2004-03-01
EMA product numberEMEA/H/C/000247

Source: European Medicines Agency — medicine data · 2026-09-30 · not reviewed by a clinician

Source: European Medicines Agency (EMA). Product information as published by EMA. Reuse terms: EMA legal notice (reproduction authorised).

Same active substance

These contain the same substance. That does not mean one can replace another — ask a pharmacist.